Metastasis-directed therapy in oligometastatic prostate cancer.
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa). Evidence from two randomized clinical trials (RCTs) and a meta-analysis show favorable toxicity profiles, and the potential to delay androgen-deprivation therapy (ADT) for up to two years in nearly half of patients with metachronous hormone-sensitive omPCa. Another RCT showed promising results of MDT as treatment-escalation method combined with androgen receptor signaling inhibitors (ARSI) in first-line treatment for castration-resistant omPCa.Surveys by radiation oncologists and consensus guidelines advocate for MDT across various omPCa scenarios. Multiple single-arm trials present encouraging results; however, the evidence for the benefit of MDT is still weak requiring further investigation to assess its impact on pivotal endpoints, such as survival and quality of life. MDT is a promising approach in omPCa, and can be used to defer ADT in newly diagnosed metachronous omPCa patients, or to add to ARSI treatment at first diagnosis of castration-resistance. Ongoing prospective trials are needed to guide its optimal utilization in other settings, and patients should be informed about the evolving landscape of systemic therapies with proven survival benefits alongside MDT options.
Identifiants
pubmed: 38426229
doi: 10.1097/MOU.0000000000001169
pii: 00042307-990000000-00142
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 2020; 6:650–659.
Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018; 36:446–453.
Miszczyk M, Rajwa P, Yanagisawa T, et al. The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies. Eur Urol 2024; 85:125–138.
Rogowski P, Trapp C, von Bestenbostel R, et al. Radiotherapy in oligometastatic prostate cancer-a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol 2022; 198:727–734.
Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020; 21:e18–e28.
Zilli T, Achard V, Dal Pra A, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol 2022; 176:199–207.
Nevens D, Jongen A, Kindts I, et al. Completeness of reporting oligometastatic disease characteristics in the literature and influence on oligometastatic disease classification using the ESTRO/EORTC Nomenclature. Int J Radiat Oncol Biol Phys 2022; 114:587–595.
Francolini G, Gaetano Allegra A, Detti B, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol 2023; 41:5561–5568.
Hao C, Ladbury C, Lyou Y, et al. Long-term outcomes of patients on a phase ii prospective trial of oligometastatic hormone-sensitive prostate cancer treated with androgen deprivation and external beam radiation. Int J Radiat Oncol Biol Phys 2022; 114:705–710.
Reyes DK, Trock BJ, Tran PT, et al. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multimodal total eradication therapy in men with synchronous oligometastatic prostate cancer. Med Oncol 2022; 39:63.
Chang Y, Zhao X, Xiao Y, et al. Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial. Front Med 2023; 17:231–239.
Deodato F, Pezzulla D, Cilla S, et al. Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis. Clin Transl Oncol 2022; 24:1177–1183.
Kwan EM, Spain L, Anton A, et al. Avelumab Combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the Phase 2 ICE-PAC Clinical Trial. Eur Urol 2022; 81:253–262.
Pan J, Wei Y, Zhang T, et al. Stereotactic radiotherapy for lesions detected via 68Ga-prostate-specific membrane antigen and 18F-fluorodexyglucose positron emission tomography/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study. Eur Urol Oncol 2022; 5:420–427.
Dearnaley D, Hinder V, Hijab A, et al. Observation versus screening spinal MRI and preemptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2022; 23:501–513.
Deek MP, Van Der Eecken K, Sutera P, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 2022; 40:3377–3382.
Glicksman RM, Ramotar M, Metser U, et al. Extended results and independent validation of a phase 2 trial of metastasis-directed therapy for molecularly defined oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys 2022; 114:693–704.
Hölscher T, Baumann M, Kotzerke J, et al. Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive oligometastatic prostate cancer: the OLI-P Phase 2 Clinical Trial. Eur Urol Oncol 2022; 5:44–51.
Rajwa P, Yanagisawa T, Gruber M, et al. Surgical metastasectomy for visceral and bone prostate cancer metastases: a mini-review. Eur Urol Focus 2023; 9:232–235.
Rajwa P, Robesti D, Chaloupka M, et al. Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a Multicenter European Study. Eur Urol Oncol 2023.
Bianchi L, Ceci F, Balestrazzi E, et al. PSMA-PET guided treatment in prostate cancer patients with oligorecurrent progression after previous salvage treatment. Cancers (Basel) 2023; 15:207.
Mercier C, Claessens M, De Troyer B, et al. Survival outcomes and pattern of relapse after SABR for oligometastatic prostate cancer. Front Oncol 2022; 12:863609.
Pastorello E, Nicosia L, Cuccia F, et al. PSMA-PET/CT-based stereotactic body radiotherapy (SBRT) in the treatment of uncomplicated non-spinal bone oligometastases from prostate cancer. Cancers (Basel) 2023; 15:2800.